A safe coronavirus 2019 disease (COVID-19) vaccine that can be administered to most of the pediatric population is a necessity for ending the pandemic, but trials for younger children have not occurred. The president of the American Academy of Pediatrics (AAP) wrote to key COVID-19 officials about the need to change this.
As the 2020-2021 influenza season loomed, many in health care worried that the seasonal disease would add to the extraordinary burden of coronavirus disease 2019 and create a perfect storm. Have various prevention strategies helped prevent this potential issue?
Vaccine hesitancy is nothing new in pediatrics. However, the increased hesitancy for the COVID-19 vaccine could prove problematic.
Improving influenza vaccination coverage is important for all children, but some are at greater risk for poorer outcomes. A review examines whether interventions can improve vaccine coverage.
A report examines if the influenza and pneumococcal vaccine has a protective effect against COVID-19.
The American Academy of Pediatrics (AAP) has issued initial guidance for COVID-19 vaccination in pediatrics.
Moderna has announced further research into whether a booster shot could provide additional protection with new COVID-19 variants.
The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.
Social distancing measures may have helped slow the spread of COVID-19 in the early days of the pandemic, but an investigation indicates an unintended and potentially problematic consequence: a decline in vaccination.
Following the green light from the vaccine advisory committee, the US Food and Drug Administration has given emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine, making it the first vaccine for COVID-19 approved for use in the United States.
The US Food and Drug Administration (FDA) vaccine committee has given the green light to the the Pfizer/BioNTech vaccine, meaning approval may happen in a matter of days.
The United States has been working on increasing human papillomavirus (HPV) vaccine coverage, with many potential interventions suggested. Are these interventions both effective and cost-effective?
The hepatitis B vaccine represents the best way to prevent the disease, which has no cure. An investigation looks at how long vaccine-linked immunity might last.
Vaccine hesitancy has led to reductions in many childhood vaccines. A report offers insight into how it impacts influenza vaccination.
Pfizer and BioNTech have released interim information on their Phase 3 COVID-19 vaccine trial.
With a rise in vaccine hesitancy, it’s more important than ever to have strong vaccine adherence. A poster at the virtual 2020 ID Week looks at how vaccine type can impact diphtheria, tetanus, and acellular pertussis (DTaP) vaccination.
The influenza vaccine has been recommended as a key way to reduce severe influenza in children. An investigation examines how effective the 2018-2019 vaccine was in preventing hospitalization and emergency department visits.
The 2020-2021 influenza season will be a strange one because of COVID-19. The National Foundation for Infectious Disease (NFID) aired a webcast that addressed how important the influenza vaccine was going to be to keep people safe during uncertain times.
Human papillomavirus (HPV) vaccination coverage has lagged in the United States. A report looks at whether the coverage will meet the Healthy People 2020 goal.
Dr. Tina Tan addresses the recent change that allows pharmacists to administer vaccinations to pediatric patients.
The 2020-2021 influenza season is fast approaching and the American Academy of Pediatrics (AAP) has issued their annual recommendations.
Contemporary Pediatrics sat down with Andrew J. Schuman, MD, to discuss vaccine hesitancy and how those sentiments could impact the future COVID-19 vaccine.
This is the critical moment in time for all health care providers to proactively stop this potential public health nightmare by speaking with all parents and adolescents about the absolute need for everyone to receive the influenza vaccine.
The US government has entered into an agreement to acquire the first 100 doses of a COVID-19 vaccine candidate developed by Moderna, Inc., pending approval by the US Food and Drug Administration.
As the COVID-19 pandemic continues, a new question arises: should schools with in-person classes require students and their family to get the flu vaccine?
